© 2005 European Society of Cardiology
Cardiac PPAR
expression in patients with dilated cardiomyopathy
a Center for Cardiovascular Research (CCR), Institute of Pharmacology and Toxicology, Charité-Universitätsmedizin Berlin CCM, Hessischestr. 3-4, 10115 Berlin, Germany
b Department of Molecular Biology, University of Texas Southwestern Medical Center Dallas, TX 75390-9148, United States
c German Heart Institute, Department of Cardiothoracic and Vascular Surgery Augustenburger Platz 1, 13353 Berlin, Germany
d Center for Cardiovascular Research (CCR), Cardiovascular Disease in Women, Charité-Universitätsmedizin Berlin, CCM Hessischestr. 3-4, 10115 Berlin, Germany
* Corresponding author. Center for Cardiovascular Research (CCR), Cardiovascular Disease in Women, Charité-Universitätsmedizin Berlin CCM, Hessischestr. 3-4, 10115 Berlin, Germany. Tel.: +49 30 450 525172; fax: +49 30 450 525972. E-mail address: vera.regitz-zagrosek{at}charite.de
 |
Abstract |
|---|
Background: The peroxisome proliferator-activated receptor alpha (PPAR
) is a central regulator of myocardial fatty acid (FA) metabolism implicated in the pathogenesis of heart failure.
Aims: To characterize PPAR regulation in human dilated cardiomyopathy (DCM), we studied the expression of cardiac PPAR, cardiac carnitine palmitoyl-transferase I (CPT-1), a major PPAR target gene, and of the cardiac glucose transporter GLUT-4 in patients with DCM.
Methods: Left ventricular biopsies were taken from patients with DCM (n=16) and control subjects (n=15), and mRNA expression was quantitated using real-time PCR (SYBR®Green) and protein expression was measured by Western immunoblotting.
Results: Left ventricular PPAR mRNA levels were significantly increased in the DCM group compared to the control group (136±25.4% vs. control, p<0.01). Consistently, DCM patients had a significantly higher cardiac CPT-1 mRNA expression (147±51% vs. control, p<0.05) compared to the control group. Cardiac GLUT-4 expression was similar in both groups.
Conclusion: Elevated cardiac PPAR levels followed by an induction of cardiac CPT-1 expression may result in increased fatty acid metabolism for cardiac energy production in DCM, suggesting a specific cardiac metabolic program in human DCM compared to other types of cardiomyopathy.
Key Words: Peroxisome proliferator-activated receptor alpha • Dilated cardiomyopathy • Fatty acids • Cardiac metabolism
Received March 11, 2005; Revised July 20, 2005; Accepted September 6, 2005
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. Djouadi, Y. Lecarpentier, J.-L. Hebert, P. Charron, J. Bastin, and C. Coirault A potential link between peroxisome proliferator-activated receptor signalling and the pathogenesis of arrhythmogenic right ventricular cardiomyopathy Cardiovasc Res, October 1, 2009; 84(1): 83 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. van Bilsen, F. A. van Nieuwenhoven, and G. J. van der Vusse Metabolic remodelling of the failing heart: beneficial or detrimental? Cardiovasc Res, February 15, 2009; 81(3): 420 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Fliegner, D. Westermann, A. Riad, C. Schubert, E. Becher, J. Fielitz, C. Tschope, and V. Regitz-Zagrosek Up-regulation of PPAR{gamma} in myocardial infarction Eur J Heart Fail, January 1, 2008; 10(1): 30 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ashrafian, M. P. Frenneaux, and L. H. Opie Metabolic Mechanisms in Heart Failure Circulation, July 24, 2007; 116(4): 434 - 448. [Abstract] [Full Text] [PDF]
|
|